Vanda puts anxiety drug’s development on ice after Phase III fail

This comes as many pharma companies fail to crack the SAD indication, with little innovation seen in the space in recent years. This comes as many pharma companies fail to crack the SAD indication, with little innovation seen in the space in recent years. Vanda has put the late-stage programme for VQW-765 in SAD on ice at it assesses the full dataset. Credit: omahgrafisgk / Shutterstock.com. Vanda Pharmaceuticals has hit pause on a late-stage programme evaluating its small molecule drug, VQW-765, after it failed to demonstrate a significant impact in patients with social anxiety disorder (SAD). Through the Phase III…

Source: Clinical Trials Arena